<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the quarterly period ended SEPTEMBER 30, 1998
---------------------------
or
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from ___________________ to _____________________
Commission file number 0-16752
MEDSTONE INTERNATIONAL, INC.
- --------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
DELAWARE 66-0439440
- --------------------------------------------------------------------------------
(State or other jurisdiction (I.R.S. Employer
of incorporation or organization) Identification No.)
100 COLUMBIA, SUITE 100, ALISO VIEJO, CALIFORNIA 92718
- --------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (949) 448-7700
--------------
NOT APPLICABLE
- --------------------------------------------------------------------------------
(Former name, former address and former fiscal year,
if changed, since last report)
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports) and (2) has been subject to such filing
requirements for the past 90 days.
Yes X No
--- ---
The number of shares of the Common Stock of the registrant outstanding as of
November 2, 1998 was 5,068,655.
<PAGE> 2
MEDSTONE INTERNATIONAL, INC.
INDEX TO FORM 10-Q
PART I. FINANCIAL INFORMATION
<TABLE>
<CAPTION>
Page No.
--------
<S> <C>
Item 1. Financial Statements:
Condensed Consolidated Balance Sheets September 30, 1998
(Unaudited) and December 31, 1997 3
Condensed Consolidated Statements of Income (Unaudited)
Three and Nine Months Ended September 30, 1998 and 1997 4
Condensed Consolidated Statement of Stockholders' Equity
(Unaudited) Nine Months Ended September 30, 1998 5
Condensed Consolidated Statements of Cash Flows (Unaudited)
Nine Months ended September 30, 1998 and 1997 6
Notes to Unaudited Condensed Consolidated Financial Statements 7
Item 2. Management's Discussion and Analysis of Financial Condition
and Results of Operations 11
PART II. OTHER INFORMATION
Item 1. Legal Proceedings 15
Item 2. Changes in Securities 15
Item 3. Defaults Upon Senior Securities 15
Item 4. Submission of Matters to a Vote of Security Holders 15
Item 5. Other Information 16
Item 6. Exhibits and Reports on Form 8-K 16
Signatures 17
</TABLE>
2
<PAGE> 3
MEDSTONE INTERNATIONAL, INC.
CONSOLIDATED BALANCE SHEETS
<TABLE>
<CAPTION>
SEPTEMBER 30, DECEMBER 31,
1998 1997
------------ ------------
(Unaudited)
<S> <C> <C>
ASSETS
Current assets:
Cash and cash equivalents $ 2,854,713 $ 1,125,009
Short-term investments 8,456,010 9,900,909
Accounts receivable, less allowance for doubtful
accounts of $557,000 and $535,000 in 1998 and
1997, respectively 4,026,140 3,120,787
Inventories 2,985,169 2,680,220
Deferred tax assets 891,507 891,507
Income taxes receivable 64,112 632,851
Prepaid expenses and other current assets 445,401 455,974
------------ ------------
Total current assets 19,723,052 18,807,257
Property and equipment:
Lithotripters 9,403,928 8,524,314
Equipment 1,005,003 815,585
Furniture and fixtures 782,435 821,565
Leasehold improvements 145,007 138,698
------------ ------------
11,336,373 10,300,162
Less accumulated depreciation and amortization (5,937,286) (4,721,618)
------------ ------------
Net property and equipment 5,399,087 5,578,544
------------ ------------
Goodwill, net 3,203,112 3,266,162
Other assets, net 501,494 36,425
------------ ------------
$ 28,826,745 $ 27,688,388
============ ============
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable $ 426,033 $ 887,740
Accrued expenses 484,296 210,421
Accrued income taxes 539,702 --
Accrued payroll expenses 339,146 239,504
Customer deposits 38,625 132,699
Deferred revenue 826,416 1,080,899
------------ ------------
Total current liabilities 2,654,218 2,551,263
Deferred tax liabilities 649,524 649,524
Minority interest 367,090 366,654
Stockholders' equity:
Common stock - $.004 par value, 20,000,000 shares
authorized, 5,644,250 and 5,634,788 shares issued
and outstanding at September 30, 1998 and
December 31, 1997, respectively 22,577 22,539
Additional paid-in capital 19,041,595 18,998,260
Accumulated earnings 10,860,749 7,436,263
Stock purchase note receivable -- (134,800)
Accumulated other comprehensive income (loss) 5,503 (579)
Treasury stock (561,300 shares at cost at September 30,
1998 and 268,800 shares at December 31, 1997) (4,774,511) (2,200,736)
------------ ------------
Total stockholders' equity 25,155,913 24,120,947
------------ ------------
$ 28,826,745 $ 27,688,388
============ ============
</TABLE>
See accompanying notes.
3
<PAGE> 4
MEDSTONE INTERNATIONAL, INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(UNAUDITED)
<TABLE>
<CAPTION>
THREE MONTHS ENDED NINE MONTHS ENDED
SEPTEMBER 30, SEPTEMBER 30,
------------------------------ -------------------------------
1998 1997 1998 1997
------------ ------------ ------------ ------------
<S> <C> <C> <C> <C>
Revenues:
Net equipment sales $ 495,000 $ 473,550 $ 2,144,500 $ 2,076,850
Procedures, maintenance fees and
fee-for-service 5,633,029 5,048,102 15,836,159 13,820,204
Interest income 135,298 133.447 402,309 385,023
------------ ------------ ------------ ------------
Total revenues 6,263,327 5,655,099 18,382,968 16,282,077
Costs and expenses:
Cost of equipment sales 621,687 328,239 1,900,803 1,511,810
Costs of procedures and
maintenance fees 2,217,078 1,974,357 6,652,349 5,396,725
Research and development 243,049 248,410 730,883 653,413
Selling 422,249 541,588 1,573,647 1,787,279
General and administrative 505,516 536,108 1,522,872 1,726,728
Goodwill amortization 21,017 22,087 63,050 55,278
Other (income) expense 22,080 -- (97,984) --
------------ ------------ ------------ ------------
Total costs and expenses 4,052,676 3,650,789 12,345,620 11,131,233
------------ ------------ ------------ ------------
Income before provision for
income taxes 2,210,651 2,004,310 6,037,348 5,150,844
Provision for income taxes 797,000 733,000 2,144,000 1,782,000
Minority interest 140,556 121,061 468,862 335,644
------------ ------------ ------------ ------------
Net income $ 1,273,095 $ 1,150,249 $ 3,424,486 $ 3,033,200
============ ============ ============ ============
Earnings per share:
Basic $ 0.25 $ 0.21 $ 0.66 $ 0.56
============ ============ ============ ============
Diluted $ 0.25 $ 0.21 $ 0.65 $ 0.55
============ ============ ============ ============
Number of shares used in the computation of
earnings per share:
Basic 5,124,050 5,352,862 5,194,480 5,398,348
============ ============ ============ ============
Diluted 5,177,086 5,532,980 5,305,554 5,489,753
============ ============ ============ ============
</TABLE>
See accompanying notes.
4
<PAGE> 5
MEDSTONE INTERNATIONAL, INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
<TABLE>
<CAPTION>
COMMON STOCK
-------------------- ADDITIONAL
NUMBER OF PAID-IN ACCUMULATED STOCK PURCHASE
SHARES AMOUNT CAPITAL EARNINGS NOTE RECEIVABLE
--------- ------- ----------- ---------- ---------------
<S> <C> <C> <C> <C> <C>
BALANCE AT DECEMBER 31, 1997 5,365,988 $22,539 $18,998,260 $7,436,263 $(134,800)
Common stock options exercised 9,462 38 43,335 -- --
Treasury stock repurchased (292,500) -- -- -- --
Repayment of stock purchase
note receivable -- -- -- -- 134,800
Unrealized gain on short-term
investments -- -- -- -- --
Net income -- -- -- 3,424,486 --
--------- ------- ----------- ---------- ---------
BALANCE AT SEPTEMBER 30, 1998
(UNAUDITED) 5,082,950 $22,577 $19,041,595 $10,860,749 $ --
========= ======= =========== =========== =========
</TABLE>
<TABLE>
<CAPTION>
ACCUMULATED
OTHER
COMPREHENSIVE TREASURY
INCOME (LOSS) STOCK TOTAL
------------- ------------ -----------
<S> <C> <C> <C>
BALANCE AT DECEMBER 31, 1997 $ (579) $(2,200,736) $24,120,947
Common stock options exercised -- -- 43,373
Treasury stock repurchased -- (2,573,775) (2,573,775)
Repayment of stock purchase
note receivable -- -- 134,800
Unrealized gain on short-term
investments 6,082 -- 6,082
Net income -- -- 3,424,486
------ ----------- -----------
BALANCE AT SEPTEMBER 30, 1998
(UNAUDITED) $5,503 $(4,774,511) $25,155,913
====== =========== ===========
</TABLE>
See accompanying notes.
5
<PAGE> 6
MEDSTONE INTERNATIONAL, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
NINE MONTHS ENDED SEPTEMBER 30, 1998 AND 1997
(UNAUDITED)
<TABLE>
<CAPTION>
1998 1997
------------ ------------
<S> <C> <C>
Cash flows from operating activities:
Net income .............................................. $ 3,424,486 $ 3,033,200
Adjustments to reconcile net income to net
cash provided (used) by operating activities:
Depreciation and amortization ..................... 1,435,777 1,186,994
Minority interest in partnership .................. 468,862 335,644
Provision for doubtful accounts ................... 75,000 191,000
Changes in assets and liabilities:
Accounts receivable ............................ (980,353) (1,630,950)
Inventories .................................... (304,949) (31,515)
Notes receivable ............................... -- 875,000
Deferred tax assets ............................ -- 369,109
Prepaid expenses and other current assets ...... 10,573 16,786
Accounts payable and accrued expenses .......... (88,190) (1,085,881)
Accrued income taxes ........................... 1,108,441 (169,205)
Deferred revenue ............................... (254,483) (95,800)
Customer deposits .............................. (94,074) --
Other, net ..................................... 4,674 (96,620)
------------ ------------
Net cash provided by (used in) operating activities 4,805,764 2,897,762
------------ ------------
Cash flows from investing activities:
Purchase of marketable securities ....................... (16,140,915) (24,704,084)
Sale of marketable securities ........................... 17,591,896 23,225,428
Purchase of subsidiary .................................. -- (2,300,000)
Investment by minority in partnership ................... (470,800) 201,963
Distribution of minority interest ....................... (467,369) (234,500)
Investment in subsidiaries .............................. (470,800) --
Purchase of property and equipment ...................... (1,239,134) (637,458)
Disposals of property and equipment ..................... 45,864 1,288
------------ ------------
Net cash provided by (used in) investing activities . (680,458) (4,447,363)
------------ ------------
Cash flows from financing activities:
Proceeds from issuance of common stock .................. 43,373 121,959
Purchase of Treasury Stock .............................. (2,573,775) (1,228,575)
Stock purchase note payment ............................. 134,800 --
------------ ------------
Net cash provided by (used in) financing activities (2,395,602) (1,106,616)
------------ ------------
Net increase (decrease) in cash and cash equivalents ........ 1,729,704 (2,656,217)
Cash and cash equivalents at beginning of period ............ 1,125,009 3,906,961
------------ ------------
Cash and cash equivalents at end of period .................. $ 2,854,713 $ 1,250,744
============ ============
Supplemental cash flow disclosures:
Cash paid during the period for:
Income taxes ............................................ $ 1,198,309 $ 1,437,699
Interest ................................................ $ 0 $ 0
</TABLE>
See accompanying notes.
6
<PAGE> 7
MEDSTONE INTERNATIONAL, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 1998
A. BASIS OF PRESENTATION
The accompanying consolidated financial statements include the accounts
of Medstone International, Inc. (the Company) and its subsidiaries. All
significant intercompany transactions and accounts have been eliminated.
In the opinion of the Company's management, the accompanying unaudited
condensed consolidated financial statements include all adjustments (which
consist only of normal recurring adjustments) necessary for a fair presentation
of its consolidated financial position at September 30, 1998 and consolidated
results of operations and cash flows for the periods presented. Although the
Company believes that the disclosures in these financial statements are adequate
to make the information presented not misleading, certain information and
disclosures normally included in financial statements prepared in accordance
with generally accepted accounting principles have been condensed or omitted and
should be read in conjunction with the Company's audited financial statements
included in the Company's 1997 Annual Report on Form 10-K filed with the
Securities and Exchange Commission on March 30, 1998. Results of operations for
the three and nine months ended September 30, 1998 are not necessarily
indicative of results to be expected for the full year.
The preparation of financial statements in accordance with generally
accepted accounting principles requires management to make assumption that
affect the amounts reported in the financial statements and accompanying notes.
Actual results could differ from these estimates.
B. RECENT ACCOUNTING PRONOUNCEMENTS
ADOPTION OF FINANCIAL ACCOUNTING STANDARDS NO. 130
As of January 1, 1998, the Company adopted Statement of Financial
Accounting Standards No. 130, Reporting Comprehensive Income (SFAS 130). SFAS
No. 130 establishes new rules for the reporting and display of comprehensive
income and its components; however, the adoption of this Statement had no impact
on the Company's net income or stockholders' equity. SFAS No. 130 requires
unrealized gains or losses on available-for-sale securities, which prior to
adoption were reported separately in shareholders' equity, to be included in
other comprehensive income. Prior financial statements have been reclassified to
conform to the requirements of SFAS No. 130.
For the three months ended September 30, 1998 and 1997, total
comprehensive income was $1,280,091 and $1,148,999, respectively. For the nine
months ended September 30, 1998 and 1997, total comprehensive income was
$3,430,568 and $3,034,380, respectively.
7
<PAGE> 8
The components of comprehensive income, net of related tax, are as
follows:
<TABLE>
<CAPTION>
THREE MONTHS ENDED NINE MONTHS ENDED
SEPTEMBER 30, SEPTEMBER 30,
---------------------------- ----------------------------
1998 1997 1998 1997
----------- ----------- ----------- -----------
<S> <C> <C> <C> <C>
Net income ............................. $ 1,273,095 $ 1,150,249 $ 3,424,486 $ 3,033,200
Unrealized gain (loss) on short-term
investments .......................... 6,996 (1,250) 6,082 1,180
----------- ----------- ----------- -----------
Comprehensive income ................... $ 1,280,091 $ 1,148,999 $ 3,430,568 $ 3,034,380
=========== =========== =========== ===========
</TABLE>
The components of accumulated other comprehensive income (loss), net of
related tax, are as follows:
<TABLE>
<CAPTION>
SEPTEMBER 30, DECEMBER 31,
1998 1997
-------------- -----------
<S> <C> <C>
Unrealized gain/(loss) on short-term
investments............................ $5,503 $(579)
------ -----
Accumulated other comprehensive
gain/(loss)............................ $5,503 $(579)
====== =====
</TABLE>
PENDING ADOPTION OF FINANCIAL STANDARDS NO. 131
In June, 1998, the Financial Accounting Standards Board issued Statement
of Financial Accounting Standards No. 131, Disclosures about Segments of an
Enterprise and Related Information (SFAS 131). SFAS No. 131 establishes
standards for the way that public business enterprises report information about
segments. SFAS No.131 also establishes standards for related disclosures about
products and services, geographic areas, and major customers. SFAS No. 131 is
effective for financial statements for fiscal years beginning after December 15,
1997. Management has not completed its review of SFAS No. 131, while adoption of
SFAS No. 131 may result in more reported segments than are currently reported,
the Company does not expect that it will have an impact on the Company=s results
of operations, financial position or cash flows.
C. PER SHARE INFORMATION
The Company has adopted SFAS No. 128 "Earnings Per Share," and applied
this pronouncement to all periods presented. This statement requires the
presentation of both basic and diluted net income per share for financial
statement purposes. Basic net income per share is computed by dividing income
available to common stockholders by the weighted average number of common shares
outstanding. Diluted net income per share includes the effect of the potential
shares outstanding, including dilutive stock options and warrants using the
treasury stock method. All earnings per share amounts for all periods have been
restated to conform with the SFAS No. 128 requirements and the accounting rules
set forth in Staff Accounting Bulletin 98 issued by the Securities and Exchange
Commission on February 3, 1998.
8
<PAGE> 9
The following table sets forth the computation of earnings per share:
<TABLE>
<CAPTION>
THREE MONTHS ENDED NINE MONTHS ENDED
SEPTEMBER 30, SEPTEMBER 30,
------------------------ --------------------------
1998 1997 1998 1997
----------- ----------- ----------- -----------
<S> <C> <C> <C> <C>
Numerator: Net income $ 1,273,095 $ 1,150,249 $ 3,424,486 $ 3,033,200
=========== =========== =========== ===========
Denominator for weighted
average shares
outstanding 5,124,050 5,352,862 5,194,480 5,398,348
Basic earnings per share $ .25 $ .21 $ .66 $ .56
=========== =========== =========== ===========
Effect of dilutive securities:
Weighted average shares
outstanding 5,124,050 5,352,862 5,194,480 5,398,348
Stock options 53,036 180,118 111,074 91,405
----------- ----------- ----------- -----------
Denominator for diluted
earnings per share 5,177,086 5,532,980 5,305,554 5,489,753
=========== =========== =========== ===========
Diluted earnings per share $ .25 $ .21 $ .65 $ .55
=========== =========== =========== ===========
</TABLE>
Common equivalent shares result from the assumed exercise of outstanding
dilutive securities when applying the treasury stock method. Fully diluted per
share information is not presented for periods in which the effect is
antidilutive.
D. INVENTORIES
At September 30, 1998 and December 31, 1997, inventories consisted of
the following:
<TABLE>
<CAPTION>
SEPTEMBER 30, DECEMBER 31,
1998 1997
------------- ------------
<S> <C> <C>
Raw materials $1,900,493 $1,645,902
Work in process 146,904 260,773
Finished goods 937,772 773,545
---------- ----------
$2,985,169 $2,680,220
========== ==========
</TABLE>
E. CONTINGENCIES
From time to time, the Company is subject to legal actions and claims
for personal injuries or property damage related to patients who use its
products. The Company has obtained a liability insurance policy providing
coverage for product liability and other claims. Management does not believe
that the resolution of any current proceedings will have a material financial
impact on the Company or the consolidated financial statements.
9
<PAGE> 10
F. STOCK REPURCHASE PLAN
On August 13, 1998 the Company announced a new stock repurchase
program of up to 100,000 shares of its Common Stock after having substantially
completed the repurchase plan announced on March 29, 1996. For the quarter ended
September 30, 1998, the Company has repurchased 74,200 shares at a cost of
$473,256. Since inception of the repurchase programs, the Company has
repurchased a total of 561,300 shares at a cost of $4,774,511. All shares are
currently held in treasury.
10
<PAGE> 11
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
RESULTS OF CONSOLIDATED OPERATIONS
GENERAL
Medstone is a provider of extracorporeal shockwave therapy. Medstone
manufactures, markets and maintains extracorporeal shockwave therapy (ESWT)
devices, and continues to expand its Fee-for-Service Program to supply such
devices to providers on a per procedure basis. To date, the Company's
consolidated revenues have come primarily from Medstone's lithotripsy business.
The Company as a manufacturer of capital medical devices has been
vertically integrating by offering its medical devices directly to providers.
Medstone sells its ESWT devices as well as providing them on fee-for-service
procedure basis. Medstone intends to continue the growth of this manufacturer
direct business.
In 1996, the Company acquired a 60% interest in Northern Nevada, a
lithotripsy partnership which deals directly with patient and insurers and also
founded UPR as a majority-owned subsidiary of the Company, to expand the
Company's service orientation to the urologist practitioner. In March 1997 the
Company acquired a 60% interest in Southern Idaho Lithotripsy Associates, LLC,
another provider of lithotripsy services.
RESULTS OF OPERATIONS
Three Months Ended September 30, 1998 Compared to Three Months Ended
September 30, 1997
The Company recognized revenue of $6.3 million in the third quarter of
1998 or an 11% increase compared to $5.7 million in the corresponding period of
1997. Equipment and equipment upgrade revenues increased by 4% due to higher
average unit selling prices for one unit shipped in the third quarter of 1998,
when compared to one unit shipped in the comparable period of 1997. Also
increasing by 12% were the revenues from the Company's maintenance, procedure
and fee-for-service activities as the number of patients treated on the
Company's lithotripters in the United States reached a record level in the third
quarter of 1998 compared to the comparable period in 1997.
Interest income increased by 1% in the three months ended September 30,
1998 compared to the same period in 1997 due to higher average invested
balances, partially offset by falling interest yields.
11
<PAGE> 12
Cost of sales on equipment and equipment upgrade sales increased to 125%
of sales in the three months ended September 30, 1998, compared to 69% of sales
in the comparable period of the prior year due costs of equipment and
installation of a foreign unit. Recurring revenue costs of sales remained at 39%
in the three months ended September 30, 1998 when compared to the same period in
the prior year. Overall cost of sales, as a percentage of revenue (excluding
interest), increased to 46% in the third of 1998 compared to 41% in the third
quarter of 1997.
Research and development costs remained level in the third quarter of
1998 compared to the same quarter to 1997 due to higher expenses for payroll and
a corresponding decrease in spending for project materials for lithotripsy
products under development by the Company.
Selling and marketing expenses decreased by $119,000, or 22% in the
third quarter of 1998 when compared to 1997 due to increased bad debt expense in
1997 and lower international travel expenses in 1998.
General and administrative expenses decreased by $21,000, or 3% in the
third quarter of 1998 when compared to the third quarter of 1997 due to
reductions in payroll expenses for the United Physicians Resources subsidiary in
1998 and lower bad debt expense in the Southern Idaho and Northern Nevada
operations partially offset by higher legal costs due to ongoing litigation.
Other (income) expenses increased by $22,000 in the third quarter of
1998 compared to the same period of 1997 due to expenses associated with general
business operations.
Provision for income taxes for the third quarter of 1998 increased by
$64,000, or 8% representing a higher taxable income when compared to the same
period in the prior year.
Minority interest in subsidiaries= income increased to $141,000 in the
third quarter of 1998, compared to $121,000 in the three months ended September
30, 1997, due to improved results in the Northern Nevada and Southern Idaho
operations.
Nine Months Ended September 30, 1998 Compared to Nine Months Ended
September 30, 1997
The Company recognized revenue of $18.4 million in the nine months ended
September 30, 1998, or a 12% increase compared to $16.3 million in the
corresponding period of 1997. Equipment and equipment upgrade revenues increased
by 3%. Five units and one equipment upgrade package was shipped in both the
current year and the prior year, However, average unit sales prices increased
slightly in the current year when compared to the same period of the prior year
due to a higher sales price foreign unit shipment. Recurring revenue from
maintenance, procedure and fee-for-service activities increased by 14% in the
first nine months of 1998 when compared to the same period of the prior year due
primarily from the 9% increase in the number of patients treated on Company
owned lithotripters in the United States.
12
<PAGE> 13
Interest income increased by 4% in the nine months ended September 30,
1998 compared to the same period in 1997 due to higher average invested
balances, partially offset by falling interest yields.
Cost of sales on equipment and equipment upgrade sales increased to 88%
of sales in the nine months ended September 30, 1998, compared to 72% of sales
in the comparable period of the prior year due to higher overhead on foreign
equipment shipments. Recurring revenue costs of sales increased to 42% in the
nine months ended September 30, 1998, compared to 39% in the same period in the
prior year due to lower per patient revenue as operating costs per patient
remains stable. Overall cost of sales, as a percentage of revenue (excluding
interest), rose to 47% in the first nine months of 1998 compared to 43% in the
first nine months of 1997.
Research and development costs increased by 11%, or $77,000 in the first
nine months of 1998 compared to the same period of 1997 due to higher payroll
expenses from expanded headcount used to further the Company's efforts on new
lithotripsy products.
Sales and marketing expenses decreased by $214,000 or 11% in the nine
months ended September 30, 1998 compared to the same period of 1997 due to lower
commission expenses, lower bad debt expense and lower international travel
expenses.
General and administrative expenses decreased by $204,000, or 11% in the
first nine months of 1998 when compared to the first nine months of 1997 due to
lower payroll and staffing levels for the United Physicians Resources subsidiary
and the corresponding reduced travel expenses.
Other (income) expenses decreased by $98,000 in the nine months ended
September 30, 1998 when compared to the same period of 1997 as the Company
recognized a one-time gain in the second quarter from the transaction with joint
venture partners placing a unit on the Asian continent.
Provision for income taxes for the first nine months of 1998 represents
a 15% increase in taxable income when compared to the first nine months of 1997
along with a slightly higher effective tax rate.
Minority interest in subsidiaries' income increased to $469,000 in the
nine months ended September 30, 1998, compared to $336,000 in the nine months
ended September 30, 1997 due to the continued expansion of the activities in the
Northern Nevada and Southern Idaho operations.
Liquidity and Capital Resources
At September 30, 1998, the Company had cash and short-term investments
of approximately $11.3 million. These funds were generated from continuing
operating activities and from the Company's initial public offering in September
1988.
13
<PAGE> 14
The Company's long-term capital expenditure requirements will depend on
numerous factors, including the progress of the Company's research and
development programs, the time required to obtain regulatory approvals, the
resources that the Company devotes to the development of self-funded products,
proprietary manufacturing methods and advanced technologies, the costs of
acquisitions and/or new revenue opportunities, the ability of the Company to
obtain additional licensing arrangements and to manufacture products under those
arrangements, and the demand for its products if and when approved and possible
acquisitions of products, technologies and companies.
The Company believes that its existing working capital and funds
anticipated to be generated from operations will be sufficient to meet the cash
needs for continuation of its present operations during 1998.
YEAR 2000
The Company is aware of the issues associated with the programming code
in existing computer systems as the millenium (year 2000) approaches. The Ayear
2000" problem is pervasive and complex as virtually every computer operation
will be affected in some way by the rollover of the two digit year value to 00.
This issue is whether computer systems will properly recognize date sensitive
information when the year changes to 2000. Systems that do not properly
recognize such information could generate erroneous data or could fail.
During 1998, the Company has conducted a comprehensive review of its
computer systems and lithotripsy equipment and identified the lithotripsy
products as Year 2000 compliant using the newest computer system release. The
Company presently believes that, with conversion to a newer version of operating
software developed in 1996, coupled with the new telephone system already
installed, the year 2000 problem will not materially affect the Company's
operations, financial position or cash flows.
The Company has instituted a program where it will request certification
from its vendors that products supplied are Year 2000 compliant. The Company
continues to monitor their compliance. Although the program is not complete, the
Company does not expect, at this time, any significant impact on its operations,
or financial position.
SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
Forward-looking statements in this report, including without limitation,
statements relating to the Company's plans, strategies, objectives,
expectations, intentions and adequacy of resources, are made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Investors are cautioned that such forward-looking statements involve risks and
uncertainties including without limitation the following: (i) the Company's
plans, strategies, objections, expectations and intentions are subject to change
at any time at the discretion of the Company, (ii) the Company's plans and
results of operations will be affected by the Company's ability to manage its
growth; (iii) the Company's businesses are highly competitive and the entrance
of new competitors into or the expansion of the operations by existing
competitors in the Company's markets and other changes could adversely affect
the Company's plans and results of operations; and (iv) other risks and
uncertainties indicated from time to time in the Company's filings with the
Securities and Exchange Commission.
14
<PAGE> 15
MEDSTONE INTERNATIONAL, INC.
PART II. OTHER INFORMATION
Item 1. Legal Proceedings
Previously reported.
Item 2. Changes in Securities
None
Item 3. Defaults upon Senior Securities
None
Item 4. Submission of Matters to a Vote of Security Holders
None
Item 6. Exhibits and Reports on Form 8-K
(a) The following exhibits are included herein:
27 Financial Data Schedule
15
<PAGE> 16
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
MEDSTONE INTERNATIONAL, INC.
A Delaware corporation
Date: November 10, 1998 /s/ MARK SELAWSKI
----------------------------------
Mark Selawski
Chief Financial Officer
(Principal financial and
accounting officer)
16
<PAGE> 17
EXHIBIT INDEX
EXHIBIT
NUMBER DESCRIPTION
- ------- -----------
27 Financial Data Schedule
<TABLE> <S> <C>
<ARTICLE> 5
<MULTIPLIER> 1
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> DEC-31-1998
<PERIOD-START> JUL-01-1998
<PERIOD-END> SEP-30-1998
<CASH> 2,854,713
<SECURITIES> 8,456,010
<RECEIVABLES> 4,026,140
<ALLOWANCES> 557,000
<INVENTORY> 2,985,169
<CURRENT-ASSETS> 19,723,052
<PP&E> 11,336,373
<DEPRECIATION> 5,937,286
<TOTAL-ASSETS> 28,826,745
<CURRENT-LIABILITIES> 2,654,218
<BONDS> 0
0
0
<COMMON> 22,577
<OTHER-SE> 25,133,336
<TOTAL-LIABILITY-AND-EQUITY> 28,826,745
<SALES> 6,128,029
<TOTAL-REVENUES> 6,263,327
<CGS> 2,838,765
<TOTAL-COSTS> 1,213,911
<OTHER-EXPENSES> 140,556
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 0
<INCOME-PRETAX> 2,070,095
<INCOME-TAX> 797,000
<INCOME-CONTINUING> 1,273,095
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 1,273,095
<EPS-PRIMARY> .25
<EPS-DILUTED> .25
</TABLE>
